Northwire Canada EditionSunday, November 1, 2026
Sign inSubscribe
Northwire
⌕
Gold 3,898.90 −3.3% Silver 49.28 −5.9% Copper 6.48 −1.8% Oil 104.12 +2.1% Palladium 987.70 −1.7% HCH 1.25 −3.9% CRD 0.040 −20.0% ENEV 0.005 +0.0% MOON 5.23 −7.9% ORE 2.56 −4.8% ASE 0.620 −14.5% LKY 0.005 + SOI 0.165 −5.7% ECR 0.190 −5.0% OZ 0.240 −9.4% ELEC 0.110 +4.8% WHY 0.260 −3.7% PHD 0.030 −33.3% OMI 0.220 −10.2% EML 0.105 +0.0% TECT 1.37 −2.8% Gold 3,898.90 −3.3% Silver 49.28 −5.9% Copper 6.48 −1.8% Oil 104.12 +2.1% Palladium 987.70 −1.7% HCH 1.25 −3.9% CRD 0.040 −20.0% ENEV 0.005 +0.0% MOON 5.23 −7.9% ORE 2.56 −4.8% ASE 0.620 −14.5% LKY 0.005 + SOI 0.165 −5.7% ECR 0.190 −5.0% OZ 0.240 −9.4% ELEC 0.110 +4.8% WHY 0.260 −3.7% PHD 0.030 −33.3% OMI 0.220 −10.2% EML 0.105 +0.0% TECT 1.37 −2.8%
Technical Study Routine +

Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility

Voyageur Pharmaceuticals is advancing its North American supply chain for early-stage radiology drug development.

By The Northwire Desk — AI Analysis Jun 23, 2026 · 16:00 VM · 0.105 Voyageur Pharmaceuticals Ltd.
Executive Summary
  • Voyageur Pharmaceuticals has engaged Fluor Corporation to conduct comprehensive feasibility studies for two strategic projects aimed at establishing a vertically integrated North American supply chain for radiology contrast drugs.
  • The company has allocated US$2.35 million for the feasibility study of an iodine extraction facility in Oklahoma, developed in collaboration with Bayer AG.
  • A separate feasibility study for a planned integrated barium/iodine manufacturing facility will have its budget finalized after proprietary process testing.
  • Studies are targeted for completion in early 2027, potentially leading to a construction decision and a subsequent phase involving offtake-linked production financing from Bayer.
  • The initiative builds upon Health Canada-approved barium contrast products already generating commercial sales in Canada.
Material Impact
  • The engagement of Fluor is a logical, expected progression following the February 2026 collaboration with Bayer and the March 2026 iodine program launch.
  • It de-risks the technical and economic viability of the proposed North American supply chain but does not immediately alter the company's financial position or near-term cash flow.
  • The news is incremental to the previously announced $2.35 million Bayer funding and the $5 million private placement closed in June 2026.
  • No material change to the company's going concern status or immediate capital requirements is disclosed.
VM · Price
Company Overview
  • Voyageur Pharmaceuticals is a Canadian junior company focused on developing a vertically integrated North American supply chain for radiology contrast drugs.
  • Flagship Project 1: Frances Creek Barite Project (British Columbia). Contains an indicated resource of 214,800 tonnes at 35.2% BaSO4. A 2022 PEA projects a $464M pre-tax NPV and 168% IRR. The company has submitted a MYAB permit for bulk sampling and is advancing process validation for pharmaceutical-grade barium.
  • Flagship Project 2: Bayer Iodine Project (Oklahoma). Leverages the proprietary Mueller Process for iodine extraction from oil-field brine. Aims to produce 35 million doses/year of iodine contrast drug.
  • Commercial Status: Health Canada-approved barium contrast products are generating early commercial sales in Canada. FDA 505(b)(2) submissions for barium commenced in February 2026.
Read the original news release →

More from Voyageur Pharmaceuticals Ltd.

Oct 02, 2026 · 16:29

Voyageur Pharmaceuticals issues equity to settle $192k debt, preserving scarce cash amid a liquidity crunch.

Financings Sep 24, 2026 · 17:52

Voyageur Pharmaceuticals settles $192,000 of debt through an equity transaction to avoid insolvency.

Financings Sep 09, 2026 · 07:30

Bayer milestone injects $1M USD, but liquidity concerns persist.

Other Aug 10, 2026 · 07:00

Voyageur Pharmaceuticals validates its domestic iodine supply chain for contrast media through successful pilot extraction operations.

Production / Operations Jun 18, 2026 · 17:01

Voyageur Pharmaceuticals advances its U.S. manufacturing footprint despite facing liquidity constraints and maintaining a pre-revenue status.

Production / Operations Jun 10, 2026 · 07:31

Voyageur Pharmaceuticals secures a permit to bulk sample the Frances Creek barite deposit despite liquidity constraints and dilution concerns.

Technical Study